In Vivo Evaluation of Safety of Nanoporous Silicon Carriers Following Single and Multiple Dose Intravenous Administrations in Mice

Overview

Journal Int J Pharm

Specialties Chemistry
Pharmacology

Date 2010 Oct 2

PMID 20883755

Citations 31

Authors

T Tanaka

B Godin

R Bhavane

R Nieves-Alicea

J Gu

X Liu

C Chiappini

J R Fakhoury

S Amra

A Ewing

Q Li

I J Fidler

M Ferrari

Affiliations

Soon will be listed here.

Abstract

Porous silicon (pSi) is being extensively studied as an emerging material for use in biomedical applications, including drug delivery, based on the biodegradability and versatile chemical and biophysical properties. We have recently introduced multistage nanoporous silicon microparticles (S1MP) designed as a cargo for nanocarrier drug delivery to enable the loaded therapeutics and diagnostics to sequentially overcome the biological barriers in order to reach their target. In this first report on biocompatibility of intravenously administered pSi structures, we examined the tolerability of negatively (-32.5±3.1mV) and positively (8.7±2.5mV) charged S1MP in acute single dose (10(7), 10(8), 5×10(8) S1MP/animal) and subchronic multiple dose (10(8) S1MP/animal/week for 4 weeks) administration schedules. Our data demonstrate that S1MP did not change plasma levels of renal (BUN and creatinine) and hepatic (LDH) biomarkers as well as 23 plasma cytokines. LDH plasma levels of 145.2±23.6, 115.4±29.1 vs. 127.0±10.4; and 155.8±38.4, 135.5±52.3 vs. 178.4±74.6 were detected in mice treated with 10(8) negatively charged S1MP, 10(8) positively charged S1MP vs. saline control in single and multiple dose schedules, respectively. The S1MPs did not alter LDH levels in liver and spleen, nor lead to infiltration of leukocytes into the liver, spleen, kidney, lung, brain, heart, and thyroid. Collectively, these data provide evidence of a safe intravenous administration of S1MPs as a drug delivery carrier.

Citing Articles

Modeling of Nanotherapy Response as a Function of the Tumor Microenvironment: Focus on Liver Metastasis.

Frieboes H, Raghavan S, Godin B Front Bioeng Biotechnol. 2020; 8:1011.

PMID: 32974325 PMC: 7466654. DOI: 10.3389/fbioe.2020.01011.

Tandem-Mass-Tag Based Proteomic Analysis Facilitates Analyzing Critical Factors of Porous Silicon Nanoparticles in Determining Their Biological Responses under Diseased Condition.

Li Y, Liu Z, Li L, Lian W, He Y, Khalil E Adv Sci (Weinh). 2020; 7(15):2001129.

PMID: 32775170 PMC: 7404168. DOI: 10.1002/advs.202001129.

Systematic comparison of methods for determining the in vivo biodistribution of porous nanostructured injectable inorganic particles.

Nizzero S, Li F, Zhang G, Venuta A, Borsoi C, Mai J Acta Biomater. 2019; 97:501-512.

PMID: 31386927 PMC: 9646250. DOI: 10.1016/j.actbio.2019.08.002.

Porous Silicon as a Platform for Radiation Theranostics Together with a Novel RIB-Based Radiolanthanoid.

Jakobsson U, Makila E, Airaksinen A, Alanen O, Etile A, Koster U Contrast Media Mol Imaging. 2019; 2019:3728563.

PMID: 30992696 PMC: 6434306. DOI: 10.1155/2019/3728563.

Visible Light Assisted Organosilane Assembly on Mesoporous Silicon Films and Particles.

Rodriguez C, Munoz Noval A, Torres-Costa V, Ceccone G, Manso Silvan M Materials (Basel). 2019; 12(1).

PMID: 30609796 PMC: 6337525. DOI: 10.3390/ma12010131.

References

Serda R, Gu J, Bhavane R, Liu X, Chiappini C, Decuzzi P . The association of silicon microparticles with endothelial cells in drug delivery to the vasculature. Biomaterials. 2009; 30(13):2440-8. DOI: 10.1016/j.biomaterials.2009.01.019. View

Tasciotti E, Liu X, Bhavane R, Plant K, Leonard A, Price B . Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. Nat Nanotechnol. 2008; 3(3):151-7. DOI: 10.1038/nnano.2008.34. View

Witasp E, Kupferschmidt N, Bengtsson L, Hultenby K, Smedman C, Paulie S . Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. Toxicol Appl Pharmacol. 2009; 239(3):306-19. DOI: 10.1016/j.taap.2009.06.011. View

Nijdam A, Zianni M, Herderick E, Cheng M, Prosperi J, Robertson F . Application of physicochemically modified silicon substrates as reverse-phase protein microarrays. J Proteome Res. 2009; 8(3):1247-54. PMC: 2693459. DOI: 10.1021/pr800455y. View

CARLISLE E . Silicon: a possible factor in bone calcification. Science. 1970; 167(3916):279-80. DOI: 10.1126/science.167.3916.279. View

Liu Y, Jiao F, Qiu Y, Li W, Qu Y, Tian C . Immunostimulatory properties and enhanced TNF- alpha mediated cellular immunity for tumor therapy by C60(OH)20 nanoparticles. Nanotechnology. 2009; 20(41):415102. DOI: 10.1088/0957-4484/20/41/415102. View

Sharma S, Nijdam A, Sinha P, Walczak R, Liu X, Cheng M . Controlled-release microchips. Expert Opin Drug Deliv. 2006; 3(3):379-94. DOI: 10.1517/17425247.3.3.379. View

Dobrovolskaia M, Aggarwal P, Hall J, McNeil S . Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm. 2008; 5(4):487-95. PMC: 2613572. DOI: 10.1021/mp800032f. View

Napierska D, Thomassen L, Rabolli V, Lison D, Gonzalez L, Kirsch-Volders M . Size-dependent cytotoxicity of monodisperse silica nanoparticles in human endothelial cells. Small. 2009; 5(7):846-53. DOI: 10.1002/smll.200800461. View

10.

Ruoslahti E . Vascular zip codes in angiogenesis and metastasis. Biochem Soc Trans. 2004; 32(Pt3):397-402. DOI: 10.1042/BST0320397. View

11.

Donaldson K, Aitken R, Tran L, Stone V, Duffin R, Forrest G . Carbon nanotubes: a review of their properties in relation to pulmonary toxicology and workplace safety. Toxicol Sci. 2006; 92(1):5-22. DOI: 10.1093/toxsci/kfj130. View

12.

Martin K . The chemistry of silica and its potential health benefits. J Nutr Health Aging. 2007; 11(2):94-7. View

13.

Salonen J, Kaukonen A, Hirvonen J, Lehto V . Mesoporous silicon in drug delivery applications. J Pharm Sci. 2007; 97(2):632-53. DOI: 10.1002/jps.20999. View

14.

Tanaka T, Mangala L, Vivas-Mejia P, Nieves-Alicea R, Mann A, Mora E . Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res. 2010; 70(9):3687-96. PMC: 3202607. DOI: 10.1158/0008-5472.CAN-09-3931. View

15.

Jugdaohsingh R, Anderson S, Tucker K, Elliott H, Kiel D, Thompson R . Dietary silicon intake and absorption. Am J Clin Nutr. 2002; 75(5):887-93. DOI: 10.1093/ajcn/75.5.887. View

16.

Brown D, Wilson M, MacNee W, Stone V, Donaldson K . Size-dependent proinflammatory effects of ultrafine polystyrene particles: a role for surface area and oxidative stress in the enhanced activity of ultrafines. Toxicol Appl Pharmacol. 2001; 175(3):191-9. DOI: 10.1006/taap.2001.9240. View

17.

Absher M, Trombley L, Hemenway D, Mickey R, Leslie K . Biphasic cellular and tissue response of rat lungs after eight-day aerosol exposure to the silicon dioxide cristobalite. Am J Pathol. 1989; 134(6):1243-51. PMC: 1879948. View

18.

Lee S, Ferrari M, Decuzzi P . Shaping nano-/micro-particles for enhanced vascular interaction in laminar flows. Nanotechnology. 2009; 20(49):495101. DOI: 10.1088/0957-4484/20/49/495101. View

19.

Hall J, Dobrovolskaia M, Patri A, McNeil S . Characterization of nanoparticles for therapeutics. Nanomedicine (Lond). 2007; 2(6):789-803. DOI: 10.2217/17435889.2.6.789. View

20.

Cerami A . Inflammatory cytokines. Clin Immunol Immunopathol. 1992; 62(1 Pt 2):S3-10. DOI: 10.1016/0090-1229(92)90035-m. View